Actavis and Medicines360 have announced the approval of Liletta (levonorgestrel-releasing intrauterine system) by the FDA for use by women to...
Medicines360/Allergan announced newly published data finding that Liletta (levonorgestrel releasing intrauterine system) is highly efficacious in preventing pregnancy over five...
Allergan announced the launch of the new Liletta (levonorgestrel-releasing intrauterine system) 52 mg IUD single-handed inserter (intrauterine device), for use...
Actavis has announced that the initial results of ACCESS IUS (A Comprehensive Contraceptive Efficacy and Safety Study of an IUS)...
Allergan has announced that the U.S. FDA has accepted for filing the company's supplemental New Drug Application (sNDA) to potentially...
Medicines360 presented new six-year data from the ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), Liletta (levonorgestrel-releasing...
Allergan plc ,and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines,announced...
Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced that the FDA has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.